For most people, human metapneumovirus (hMPV) is not dangerous. It causes a cold-like illness that resolves on its own within a week or two. But for certain groups, particularly older adults in care facilities, people with blood cancers, and organ transplant recipients, hMPV can become a serious and sometimes fatal infection. The level of risk depends almost entirely on your age and immune status.
How It Compares to the Flu and RSV
hMPV often gets lumped in with RSV and influenza because all three circulate during the same winter months and cause similar symptoms. A long-running household study published in The Journal of Infectious Diseases tracked all three viruses over 12 years and found that hMPV was detected in 3.4% of respiratory illness specimens, compared to 4.4% for RSV and 6.7% for influenza A. So it’s slightly less common, but not rare.
In terms of severity, hMPV falls between RSV and the flu. People with hMPV reported about 11% fewer moderate or severe symptoms than those with influenza. On their worst day of illness, hMPV patients rated their health roughly 6 points higher on a 100-point scale compared to flu patients. That said, hMPV still knocked people out: about 42% of working adults missed work, averaging over 8 days of lost hours, which was comparable to the flu.
Who Faces the Highest Risk
The danger from hMPV concentrates in a few specific populations. A systematic review in Infectious Diseases and Therapy pooled data from 32 studies on high-risk adults and found an overall case fatality rate of 9.3%. But that number varied dramatically depending on the group.
Older adults living in long-term care facilities had the highest pooled fatality rate at 30%. People with blood cancers like leukemia or lymphoma had a fatality rate of about 23%. Recipients of bone marrow or stem cell transplants faced a rate around 14.5%. Interestingly, solid organ transplant recipients (specifically lung transplant patients in the studies reviewed) had no deaths during their study periods, suggesting the risk varies even among transplant patients.
Young children, especially those under 5, are also vulnerable to more severe illness. hMPV is a leading cause of bronchiolitis and croup in infants and toddlers. While fatal outcomes in otherwise healthy children are rare, the infection can lead to hospitalization when it causes significant breathing difficulty.
What hMPV Does to the Lungs
In mild cases, hMPV stays in the upper airways, producing the runny nose, cough, and sore throat you’d expect from any respiratory virus. The trouble starts when it moves deeper into the lungs.
When hMPV infects the lower respiratory tract, it triggers a strong inflammatory response. The immune system floods the lungs with inflammatory signals, and goblet cells (the cells that produce mucus) go into overdrive. This combination of inflammation and excess mucus can narrow or collapse small airways, making it progressively harder to breathe. In older adults and those with weakened immune systems, this process can develop into pneumonia. In people with COPD or asthma, hMPV can trigger acute flare-ups of their existing condition.
Animal research has shown that the lung inflammation from hMPV can persist well beyond the acute illness. In one study, mice still showed significant airway obstruction and hyperresponsiveness 70 days after infection, with detectable pulmonary inflammation lasting past day 154. While mouse studies don’t translate directly to humans, these findings raise concern that severe hMPV infections could contribute to longer-term airway problems, particularly in children whose lungs are still developing.
Symptoms That Signal Serious Illness
Most hMPV infections look like a bad cold: cough, congestion, mild fever, and general fatigue. These symptoms typically don’t require medical attention. The key warning sign that an hMPV infection has turned dangerous is difficulty breathing. This can look different depending on age.
In infants and toddlers, watch for rapid breathing, flaring nostrils, skin pulling inward between the ribs with each breath, or a blue tint around the lips. In adults, shortness of breath during normal activities, chest tightness, or a persistent worsening cough after the first few days of illness are reasons to seek care. If breathing becomes labored enough to require medical intervention, supplemental oxygen delivered through a nasal tube or face mask is the standard first step.
No Vaccine or Antiviral Yet
There is currently no approved vaccine or specific antiviral treatment for hMPV. Treatment is entirely supportive: rest, fluids, fever reducers, and oxygen if needed. This is one reason the virus poses a disproportionate threat to immunocompromised patients, who can’t rely on their own immune systems to clear it efficiently.
Vaccine development is underway. A Phase 1 clinical trial is currently recruiting older adults to test a combined vaccine targeting hMPV alongside RSV and parainfluenza virus type 3. Two components of that vaccine (the RSV and hMPV portions) have already been tested in people as part of an earlier study. But Phase 1 trials are the earliest stage of human testing, focused on safety rather than effectiveness, so a widely available vaccine is still years away.
How It Spreads
hMPV spreads the same way as most respiratory viruses: through droplets from coughing and sneezing, close personal contact, and touching contaminated surfaces then touching your face. Nearly everyone has been infected by age 5, and reinfections happen throughout life because immunity wanes over time. The virus circulates primarily in late winter and early spring, overlapping with flu and RSV season.
Prevention comes down to the same basics that work against other respiratory viruses. Frequent handwashing, avoiding close contact with sick individuals, and cleaning shared surfaces reduce transmission. For people who are immunocompromised or caring for high-risk individuals, these precautions matter more than usual given the lack of a vaccine or targeted treatment.
How hMPV Is Diagnosed
If you’re otherwise healthy with mild symptoms, you probably won’t be tested for hMPV specifically. Doctors typically test for it when a patient is hospitalized with a respiratory illness or when they need to identify the cause of severe symptoms. The standard method uses a respiratory viral panel, a nasal swab that can detect multiple viruses at once through genetic testing. These panels can identify hMPV alongside flu, RSV, and other common respiratory viruses in a single test.
Timing matters for accuracy. The swab needs to be collected while the virus is actively present in the respiratory tract. A poorly collected or poorly stored sample can produce a false negative. And a positive result doesn’t always mean the virus is causing your current symptoms, since viral genetic material can linger in the body after an active infection has resolved. Doctors interpret results alongside your symptoms and sometimes additional tests like chest X-rays to get the full picture.